Australia's most trusted
source of pharma news
Monday, 23 February 2026
Posted 23 February 2026 AM
Founders of Australian telehealth company Eucalyptus are cashing in by selling the company for $1.6 billion to US firm Hims & Hers.
Eucalyptus, backed by Woolworths and VC funds, made its mark filling prescriptions written via online consultations with compounded semaglutide, until the Federal Government banned the compounding of GLP-1 RAs in 2024. Hims & Hers supplied compounded semaglutide in the US, but announced this month it would cease to do so.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.